Centessa Pharmaceuticals’ (CNTA) Peer Perform Rating Reaffirmed at Wolfe Research

Wolfe Research reiterated their peer perform rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report released on Tuesday,Benzinga reports.

Other research analysts have also recently issued reports about the stock. B. Riley Financial raised their price objective on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Chardan Capital reissued a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Truist Financial upped their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, January 29th. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Finally, Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $39.72 on Tuesday. The stock has a fifty day moving average price of $26.29 and a 200 day moving average price of $25.24. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock has a market cap of $5.80 billion, a PE ratio of -21.70 and a beta of 1.55. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). Sell-side analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company’s stock, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 349,073 shares of company stock worth $9,429,412 in the last three months. Company insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. grew its position in Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after acquiring an additional 1,516 shares during the period. Wells Fargo & Company MN grew its position in Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares during the period. Finally, Knott David M Jr acquired a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

More Centessa Pharmaceuticals News

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep‑medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short‑term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near‑term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12‑month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.